Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis

Neoplasia

Volumn 8, Issue 3, 2006, Pages 199-206

  McPhail, Lesley D ^a   McIntyre, Dominick J O ^a   Ludwig, Christian ^a   Kestell, Philip ^b   Griffiths, John R ^a   Kelland, Lloyd R ^c   Robinson, Simon P ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c Antisoma Research Ltd   (United Kingdom)

Author keywords

DCE MRI; DMXAA; Perfusion; Serotonin; Vascular targeting

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; BIOLOGICAL MARKER; GADOLINIUM; VASCULAR TARGETING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD VESSEL INJURY; BLOOD VESSEL PERMEABILITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POTASSIUM TRANSPORT; PRIORITY JOURNAL; PROLACTINOMA; RAT; TUMOR BLOOD FLOW; TUMOR NECROSIS;

EID: 33646342514     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.05739     Document Type: Article

References (32)

1. Siemann DW, Chaplin DJ, and Horsman MR (2004). Vascular-targeting therapies for treatment of malignant disease. Cancer 100, 2491-2499.
2. Tozer GM, Kanthou C, and Baguley BC (2005). Disrupting tumour blood vessels. Nat Rev Cancer 5, 423-435.
3. Denekamp J and Hobson B (1982). Endothelial-cell proliferation in experimental tumours. Br J Cancer 46, 711-720.
4. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson GC, Judson IR, Knopp MV, Maxwell RJ, et al. (2005). The assessment of antiangiogenic and antivascular therapies in earlystage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92, 1599-1610.
5. Baguley BC, Zhuang Li, and Kestell P (1997). Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine and colchicine: relation to vascular effects. Oncol Res 9, 55-60.
6. Rustin G, Bradley C, Galbraith S, and Stratford M (2003). 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase 1 pharmacokinetic and pharmacodynamic study. Br J Cancer 88, 1160-1167.
7. Zhou SF, Tingle MD, Kestell P, and Paxton JW (2002). Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo. Xenobiotica 32, 87-107.
8. McPhail LD, Chung YL, Basetti M, Clark S, Griffiths JR, Kelland LR, and Robinson SP (2005). Tumour dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy. Clin Cancer Res 11, 3705-3713.
9. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, and Skipper HE (1966). Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother Rep 50, 219-244.
10. McIntyre DJO, Ludwig C, Pasan A, and Griffiths JR (2004). A method for interleaved acquisition of a vascular input function for dynamic contrast-enhanced MRI in experimental rat tumours. NMR Biomed 17, 132-143.
11. 1-weighted gradient echo images due to the spatial flip angle variation of surface coils. Magma 15, 228-229.
12. Tofts PS and Kermode AG (1991). Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 17, 357-367.
13. Evelhoch JL (1991). Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 10, 254-259.
14. Kestell P, Zhao L, Jameson MB, Stratford MR, Folkes CK, and Baguley BC (2001). Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents. Clin Chim Acta 314, 159-166.
15. Maxwell RJ, Wilson J, Prise VE, Vojnovic B, Rustin GJ, Lodge MA, and Tozer GM (2002). Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed 15, 89-98.
16. Robinson SP, McIntyre DJO, Checkley D, Tessier JJ, Howe FA, Griffiths JR, Ashton SE, Ryan AJ, Blakey DC, and Waterton JC (2003). Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 88, 1592-1597.
17. Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, Langmuir P, Wheeler C, Store A, Leadbetter J, et al. (2004). Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 10, 3650-3657.
18. Galbraith SM, Rustin JS, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, Thompson P, Hough D, Gumbrell L, and Padhani AR (2002). Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumour microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20, 3826-3840.
19. McKeage M, Fong P, Jeffery M, Ravic M, and Jameson MB (2005). DART-A phase I safety and dose-finding study of the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in the treatment of refractory tumours. Proc Am Soc Clin Oncol 3081, 212s.
20. Baguley BC (2003). Antivascular therapy of cancer: DMXAA. Lancet Oncol 4, 141-148.
21. Ferrero E, Villa A, Ferrero ME, Toninelli E, Bender JR, Pardi R, and Zocchi MR (1996). Tumor necrosis factor alpha-induced vascular leakage involves PECAM1 phosphorylation. Cancer Res 56, 3211-3215.
22. Hofmann S, Grasberger H, Jung P, Bidingmaier M, Vlotides J, Janssen OE, and Landgraf R (2002). The tumour necrosis factor-alpha induced vascular permeability is associated with a reduction of VE-cadherin expression. Eur J Med Res 30, 171-176.
23. Lejeune FJ (2002). Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability. J Clin Invest 110, 433-435.
24. Nwariaku FE, Chang J, Zhu X, Liu Z, Duffy SL, Halaihel NH, Terada L, and Turnage RH (2002). The role of p38 map kinase in tumor necrosis factor-induced redistribution of vascular endothelial cadherin and increased endothelial permeability. Shock 18, 82-85.
25. Kerkar S, Williams M, Blocksom JM, Wilson RF, Tyburski JG, and Steffes CP (2006). TNF-alpha and IL-1beta increase pericyte/endothelial cell co-culture permeability. J Surg Res (in press).
26. Watanabe N, Niitsu Y, Umeno H, Kuriyama H, Neda H, Yamauchi N, Maeda M, and Urushizaki I (1988). Toxic effect of tumour necrosis factor on tumour vasculature in mice. Cancer Res 48, 2179-2183.
27. Kallinowski F, Schaefer C, Tyler G, and Vaupel P (1989). In vivo targets of recombinant human tumour necrosis factor-alpha: blood flow, oxygen consumption and growth of isotransplanted rat tumours. Br J Cancer 60, 555-560.
28. Ching LM, Cao Z, Kieda C, Zwain S, Jameson MB, and Baguley BC (2002). Induction of endothelial cell apoptosis by the anti-vascular agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 86, 1937-1942.
29. Feng D, Nagy JA, Hipp J, Dvorak HF, and Dvorak AM (1996). Vesiculovacuolar organelles and the regulation of venule permeability to macro-molecules by the vascular permeability factor, histamine, and serotonin. J Exp Med 183, 1981-1986.
30. Thoeny HC, De Keyzer F, Vandecaveye V, Chen F, Sun X, Bosmans H, Hermans R, Verbeken EK, Boesch C, and Marchal G (2005). Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced cular versus diffusion-weighted MR imaging. Radiology 237, 492-499.
31. Zhao D, Jiang L, Hahn EW, and Mason RP (2005). Tumor physiologic response to combretastatin A4 phosphate assessed by MRI. Int J Radiat Oncol Biol Phys 62, 872-880.
32. Robinson SP, Kalber TL, Howe FA, McIntyre DJ, Griffiths JR, Blakey DC, Whittaker L, Ryan AJ, and Waterton JC (2005). Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging. Neoplasia 7, 466-474.